PAINWeek National Conference

Using data found on health care claims, researchers developed a machine learning tool that resulted in a “high level of predictive…

The risk for abuse was significantly lower among patients using Nucynta extended release than abuse-deterrent formulation opioids and non-abuse…

Approximately 16% of patients with migraine who were prescribed triptans overused the medication, according to data presented at PainWeek 2018…

A low dose of sumatriptan provided significantly higher 2-hour pain freedom and 2-hour pain relief vs. placebo, according to phase 3 trial findings…

Fremanezumab — a fully humanized monoclonal antibody targeting a calcitonin gene-related peptide that researchers said has already demonstrated…

A multimodal analgesia approach decreased the amount of opioids prescribed at discharge, adequately controlled pain and reduced hospital length of…

Oxycodone DETERx ER, an extended-release, abuse-deterrent drug, safely and effectively managed chronic pain in patients with poorly managed pain…

Patients receiving the opioid analgesic NKTR-181 had reduced back pain and exhibited low rates of opioid withdrawal, compared their counterparts who…

Compared with placebo, lasmiditan reduced migraine pain and symptoms after 2 hours for most patients with at least moderate disability, according to…

In patients with moderate to severe osteoarthritis knee pain, a single intra-articular injection of 1 mg of CNTX-4975 was well tolerated and…